Qu Biologics Granted Broad European Patent for Targeted Treatment of Multiple Cancers

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 6, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to reboot the body's immune system to treat cancer and autoimmune disease, announced it has been granted a broad European patent covering the use of vaccines derived from bacterial components to stimulate a targeted immune response to a variety of common cancers.

Qu Biologics was issued European Patent No. 1765391. The allowed claims relate to the use of antigenic determinants of bacterial pathogens for the targeted treatment of cancers of the breast, lung, colon, prostate, kidney, bone, skin, mouth, testicle, uterus, ovary, vagina, gallbladder, bladder and lymphomas associated with the head or neck, chest, abdominal cavity and the axilliary or inguinal area.

Dr. Hal Gunn, Chief Executive Officer of Qu Biologics commented, "Our SSIs aim to 'reboot' the body's immune response to cancer using immunostimulative bacterial components, representing a novel treatment approach. We are very pleased to have been granted this important broad patent which provides the foundation for the further development of SSIs for the treatment of cancer."

Qu Biologics develops immunotherapies called Site Specific Immunomodulators (SSIs), which are made of inactivated bacteria aimed at stimulating the body's own immune system against cancer and autoimmune disease. The company's SSI platform represents a promising new approach to cancer and autoimmune disease. Qu Biologics has developed multiple SSIs, each of which targets a specific tissue/organ system.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease. The company recently launched a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.